Effects of on-demand β2-agonist inhalation in moderate-to-severe asthma. A randomized controlled trial

Journal of Internal Medicine

Volumn 247, Issue 6, 2000, Pages 657-666

  Richter, B ^a   Bender, R ^b   Berger, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

Author keywords

Administration; Adrenergic beta agonists; Asthma; Inhalation; Patient education; Quality of life; Randomized controlled trials

Indexed keywords

ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FENOTEROL; SALBUTAMOL;

ACUTE DISEASE; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; SPIROMETRY; TREATMENT OUTCOME; BRONCHODILATATION; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; LUNG FUNCTION; MAJOR CLINICAL STUDY; PATIENT EDUCATION; PRIORITY JOURNAL; SYMPTOM;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FENOTEROL; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SPIROMETRY; TREATMENT OUTCOME;

EID: 0033623753     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00677.x     Document Type: Article

References (27)

1. 1 Barnes PJ. A new approach to the treatment of asthma. N Engl J Med 1989; 321: 1517-27.
2. 2 British Asthma Guidelines Coordinating Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1-24.
3. 3 Expert Panel Report II. Guidelines for Diagnosis and Management of Asthma. Final Version of the Report from the National Asthma Education and Prevention Program Updating the 1991 Expert Panel Report. National Heart, Lung and Blood Institute. Publication no. 97-4051. Bethseda, MD, USA NIH Publications, 1991.
4. 4 Sears MR, Taylor DR. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf 1994; 11: 259-83.
5. 5 Tattersfield AE. Use of beta 2 agonists in asthma: much ado about nothing? Still cause for concern. Br Med J 1994; 309: 794-5.
6. 6 Giuntini CG, Paggiaro PL. Present state of the controversy about regular inhaled beta-agonists in asthma. Eur Respir J 1995; 8: 673-8.
7. 7 Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6.
8. 8 van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. Br Med J 1991; 303: 1426-31.
9. 9 Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134-8.
10. 10 Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994; 343: 1379-82.
11. 11 Apter AJ, Reisine ST, Willard A, et al. The effect of inhaled albuterol in moderate to severe asthma. J Allergy Clin Immunol 1996; 98: 295-301.
12. 12 Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335: 841-7.
13. 13 Muehlhauser I, Richter B, Kraut D, Weske G, Worth H, Berger M. Evaluation of a structured treatment and teaching programme on asthma. J Intern Med 1991; 230: 157-64.
14. 14 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-44.
15. 15 American Thoracic Society. Standardization of spirometry -1987 update. Am Rev Respir Dis 1987; 136: 1285-98.
16. 16 Cockcroft DW, Killian DN, Mellon JA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7: 235-43.
17. 20: comparison of linear and logarithmic interpolation. Chest 1983; 84: 505-6.
18. 18 Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993; 6 (Suppl. 16): 53-83.
19. 19 Peat JK, Unger WR, Combe D. Measuring changes in logarithmic data, with special reference to bronchial responsiveness. J Clin Epidemiol 1994; 47: 1099-108.
20. 20 Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol 1992; 45: 461-72.
21. 21 Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 (Suppl. B): 25-31.
22. 22 Sears MR. Dose reduction of beta-agonists in asthma. Lancet 1991; 338: 1331-2(letter).
23. 23 Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. London, UK: Chapman & Hall, 1989.
24. 24 France LA, Lewis JA, Kay R. The analysis of failure time data in crossover studies. Statist Med 1991; 10: 1099-113.
25. 25 SAS. SAS/STAT Guide for Personal Computers, 6th edn. Cary, NC, USA: SAS Institute Inc., 1987.
26. 26 SAS. SAS Technical Report P-217, SAS/STAT Software: the PHREG Procedure, Version 6. Cary, NC, USA: SAS Institute Inc, 1991.
27. 27 Sitthi AC, Poshyachinda V. Bias. Lancet 1993; 342: 286-8.